Drug news
VEN 309 (Vetrus Biosciences) fails Phase III for treatment of Haemorrhoids
Ventrus Biosciences, Inc. has reported that its Phase III, randomized, double-blind, placebo-controlled clinical trial of iferanserin (VEN 309) in patients with Haemorrhoidal Disease did not meet its endpoints.The Company will analyze the Phase III data further but believes that its efforts will be better allocated toward the planned completion of its VEN 307 (diltiazem cream) development program in anal fissures and the beginning of further development of VEN 308 (topical phenylephrine) in fecal incontinence. Consequently, Ventrus has no immediate plans to continue development of VEN 309.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins